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A B S T R A C T
The appearance of new anti-epileptic drugs (AED) during the last decade has provided neurologists and
their patients with a greater choice, but the proof for their superiority over traditional AEDs is sparse,
especially their use in adolescence and young adulthood. We studied a group of young adults (18–27
years) with epilepsy and compared their situation in 2004 with those 5 years earlier.
Materials and methods: The participants (n = 97) answered questionnaires regarding seizure-frequency,
AED, side-effects and quality-of-life. Information was also taken from medical records.
Results: The use of new generation AEDs increased during the 5-year study period, particularly among
women. However seizure frequency had not changed signiﬁcantly over time, and compared to men the
effectiveness in controlling seizures was lower in women. The participants reported normal quality-of-
life (QOL), whichmay indicate that the increase in number of AEDs to choose from actually improved the
situation for these young adults with epilepsy. Frequency of seizures and cognitive side-effects of AEDs
were associated with a lower QOL.
Conclusions: More women than men seem to be treated with new AEDs, and that the increase in use of
new AEDs does not reduce seizure frequency in young adulthood. The effectiveness in controlling
seizures seems to be lower in women in the age group studied. Further studies are required to better
understand how epilepsy related factors interact.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The natural course of epilepsy has been studied in various
patient groups but seldom among adolescents and young adults.
Most studies on epilepsy in young people have concentrated on
childhood epilepsy and not adolescents on the verge of adulthood.
Some forms of epilepsy are more likely to start during teenage
years, including the idiopathic syndromes such as juvenile
myoclonic epilepsy. Partial syndromes such as mesial temporal
sclerosis can also have its debut in the teens. Common triggers
during this period, when there are so many new things to
experience, are sleep deprivation, photosensitivity, alcohol use,
and major stress such as school-examinations. It has been shown
that among patients with childhood-onset epilepsy one-third will
have a poor long-termoutcome in terms of persistent seizures after
remission or no remission at all [1]. Studies on the general epilepsy
population have shown that treatment is not always optimal and
that it is possible to improve the care of these patients.* Corresponding author.
E-mail address: helena.gaufﬁn@lio.se (H. Gaufﬁn).
1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.11.009In 1999, Raty et al. studied a group of young people with
uncomplicated epilepsy. Since then these adolescents have grown
into young adults. The study in 1999 showed that 42% continued to
have seizures despite of anti-epileptic drug (AED) treatment. A
British group also conﬁrmed that seizures remain uncontrolled in
up to half of all people with epilepsy in the UK [2].
Raty et al. concluded in 1999 that the treatment of young people
with epilepsy could be improved. Traditional AEDs strongly
dominated the market and the authors presumed that newly
released drugs were underused in this group. They also reported a
high rate of side-effects among patients using AEDs [3–6].
In 2001, Lhatoo et al. [7] found, in the general population with
epilepsy, few changes in medication in the face of continued
seizures, a lack of speciﬁcity in the choice of drugs and a reluctance
to use newer anti-epileptic drugs in patients with resistant
epilepsy.
There have been considerable changes in the use of AEDs over
the last decade as many new drugs have been developed and
successively more widely used. These new drugs have advantages
over to the old ones in terms of their favourable pharmacokinetics,
improved tolerability and lower potential for drug-interactions [8].
They widen our treatment spectrum and make it possible tovier Ltd. All rights reserved.
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superiority over older drugs is sparse [10]. Many researchers,
among them Brodie and French [11], have pointed out that a wider
use of new AEDs could improve the situation for many epilepsy
patients.
Traditional AEDs remain ﬁrst choice for most patients, but for
special situations and populations a new AED may be recom-
mended as reasonable ﬁrst-line therapy [12]. This includes
lamotrigine (LTG) as an alternative to valproate (VPA) in
idiopathic generalized seizures in fertile women. A Spanish study
in 2005 showed that women are more likely to be treated with a
new AED and seem to have less adverse reactions [13]. Their
results indicate that it is more difﬁcult to control seizures in
women. The underlying aetiology is an important factor as to
whether patients develop intractable seizures or not [14] but
there is no proof that there is a gender difference regarding
refractory epilepsy.
This study compared seizure frequency and AED treatment
2004 with the situation 5 years earlier amongst young people with
uncomplicated epilepsy. We also looked for differences between
the genders concerning use of AEDs, seizure-frequency, side-
effects and reported quality-of-life (QOL). We also analysed the
material for prognostic factors.
2. Materials and methods
2.1. Subjects
In 1999, Raty et al. studied adolescents at four Swedish
hospitals. Adolescents aged 13–22 with uncomplicated epilepsy
were invited to participate in that study and 82% accepted
(n = 151). Raty et al. studied the medical and psychosocial
characteristics of these young people with epilepsy. In 2004 a 5-
year follow-up study was done. These young adults, now aged 18–
27 years, were asked to complete the same questionnaires as in
1999. At the time of follow-up, 146 subjects were traceable and 97
returned the questionnaires. More women than men completed
the questionnaires.
Analyses revealed no differences between the participants and
the drop-outs with respect to socio-demographic factors, self-
esteem, sense of coherence, problem areas, competence, or in
terms of measured medical epilepsy-related factors.
2.2. Deﬁnitions
The diagnosis of epilepsy in 1999 was deﬁned as having had at
least two unprovoked epileptic seizures. Uncomplicated epilepsy
was deﬁned as epilepsy with no initially associated neurological
impairment (mental retardation or cerebral palsy).
2.3. Inclusion/exclusion criteria
To be included in the groupwhen it formed in 1999, adolescents
had to have experienced at least one epileptic seizure during the
previous year and/or to be on anti-epileptic drug treatment for
epilepsy. Exclusion criteria were diseases or handicaps that were
considered to have a substantial impact on quality-of-life. Patients
with epilepsy classiﬁed as benign childhood epilepsy were also
excluded in the original study 1999.
2.4. Instruments
A modiﬁed version of the National Hospital Seizure Severity
Scale, NHS3 (Donoghue 1994, Swedish translation Malmgren
1994) was used both in 1999 and 2004. The question about seizure
type was replaced by one where patients were asked to describetheir seizures. Three questions were added concerning seizure
frequency, drug treatment and side-effects of AED. To measure
quality-of-life in 2004 we used the generic version of Quality-of-
Life Index (QLI), written in Swedish. The instrument consists of two
parts, each containing 34 items. It measures a person’s satisfaction
with various aspects of life and how important these aspects are to
the person. It covers health and function, socio-economic status,
psychological/spiritual and family. The scale is six-graded and
ranges from 1 = very dissatisﬁed/very unimportant to 6 = very
satisﬁed/very important. The maximum score is 30. QLI has
previously been described in detail in an article published 2007
[15]. The QLI was classiﬁed as low if they scored less than 20,
intermediate if they scored between 20 and 25 and high if the total
score exceeded 25.
2.5. Procedure
Patients participating in 1999 were identiﬁed and invited by
mail to participate in the follow-up study. Those who accepted
gave their written consent. The invitation included information
about the study, four questionnaires on quality-of-life,medical and
psychosocial aspects of epilepsy, a written consent formula
regarding permission to obtain information from the patient’s
medical record and a prepaid envelope in which to mail the
response.
Patients who did not return their questionnaires within two
weeks were contacted by phone or by mail if phone-calls were not
answered. Data was also collected from the patient’s medical
records by two of the authors (H.G. and B.S.).
Classiﬁcation of epileptic seizures was made according to the
classiﬁcation of the International League Against Epilepsy (ILAE)
[16].
To classify how well the seizures were controlled we used the
same classiﬁcation as Eriksson [17]. This classiﬁcation was used in
1999 and also in 2004 to enable comparison.
(a) Good control: no seizures during the last year.
(b) Partial control: at least one seizure during the last year but not
more than one per month.
(c) Poor control: more than one seizure per month.
2.6. Analyses
For statistical analyses the Statistical Package for Social
Sciences version 12.0 was used. Frequencies were calculated
and cross-tabulations were carried out. Descriptives were pre-
sented as numbers and percentages in variables at nominal level.
Non-parametric analyses used were Mann–Whitney’s U-test,
Kruskal–Wallis test and Fisher’s exact test for comparison between
independent groups. Wilcoxon sign-ranks test was used for
comparison between dependent groups. p-Values less than 0.05
were considered signiﬁcant.
2.7. Ethics
The regional research committees of Linko¨ping and O¨rebro,
Sweden approved this study. Those who participated gave their
verbal and/or written consent. Written and verbal information
were given to all medical staff concerned.
3. Results
In 2004, 97 participants, 37 men and 60 women completed the
questionnaires. They were between 18 and 27 years old and had
suffered from epilepsy at least 5 years. Some of the participants
Table 1
Classiﬁcation of epilepsy in 2004 according to ILAE—young patients with
uncomplicated epilepsy.
Classiﬁcation of epilepsy Frequency (n)
Localization-related, symptomatic epilepsy 19
Localization-related, cryptogenic epilepsy 12
Generalized, idiopathic, childhood absence epilepsy 2
Generalized idiopathic juvenile absence epilepsy 3
Generalized idiopathic juvenile myoclonic epilepsy 7
Generalized idiopathic other generalized idiopathic
epilepsies not deﬁned
31
Generalized idiopathic epilepsy with seizures precipitated
by speciﬁc modes of action
1
Generalized symptomatic epilepsy non-speciﬁc etiology 1
Recovered from epilepsy 21
Total 97
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were all seizure-free, did not use any AEDs and reported no or only
scarce contact with their neurologist. There were more women
than men in this group (p < 0.05). There was no correlation
between the classiﬁcation set in 1999 and recovery. No signiﬁcant
differences regarding other demographic factors were shown.
Most of these participants were also seizure-free in 1999, but were
still using AEDs at that time.
The other participants (n = 76) still suffered from epilepsy and
all but one used AED.
Among those still suffering from epilepsy 41%were classiﬁed as
localisation-related epilepsy and 59% generalized epilepsy accord-
ing to Table 1.
More than half (57.9%) of these participants were seizure-free.
The groupwith pharmaco-resistent seizures had increased slightly
from 11.8% (n = 10) to 15.8% (n = 12).
Three persons had gone through ablation of the epilepsy focus
and three persons had a vagus nerve stimulator implanted. Despite
these procedures only one of these six participants had beneﬁted
substantially.
There was no signiﬁcant change in seizure frequency for the
whole group in 2004 compared to 1999. Participants that had
recovered were seizure-free even in 1999, but most of them used
medication then. There were no gender differences regarding
seizure frequency in 1999, but more men than women had good
control of seizures in 2004 (p < 0.05). Among the participants that
still used AED, 77% of the men had good control of seizures,
compared with 45% of the women. Of these men 75% usedTable 2
Control of seizures, all participants 1999 and 2004 respectively. Number of participant
Control of sei-
zures
Women (n) Men (n)
AED No
AED
Traditional
AEDa
New
AEDb
Poly-therapyc No
AED
Traditio
AEDa
Good 1999 2 27 2 4 4 15
2004 15 9 8 3 6 18
Partial 1999 2 13 2 2 1 5
2004 1 7 6 2 0 1
Poor 1999 0 4 0 2 0 2
2004 0 0 4 5 0 0
Total 1999 4 44 4 8 5 22
2004 16 16 18 10 6 19
a Traditional AED included carbamazepine, valproate, and phenytoin.
b New AED included lamotrigine, oxcarbazepine, vigabatrin, gabapentin, levetiraceta
c No participant used more than three AEDs.monotherapy with old generation AED compared with 45% of the
women.
The use of new AEDs had increased since 1999 (p < 0.05). More
women participants had received ﬁrst-line treatment with a new
generation AED than men (p < 0.05). More men than women were
still prescribed monotherapy with a traditional AED in 2004
(p < 0.05). While men used valproicacid and carbamazepine to the
same extent as in 1999 there was a shift from these substances to
the use of new AEDs in women. The old AED withdrawn was
usually substituted by lamotrigine in monotherapy or in combina-
tionwith other drugs. Of AED users in this study 54% ofwomen and
33% of men used lamotrigine at follow-up (Table 2).
Among the participants who had good control of seizures 61%
were treated with monotherapy of a traditional AED while 25%
used monotherapy with a new AED. In the group with poor control
of epilepsy nobody used monotherapy with traditional AED, while
67% used poly-therapy and 33% new AED.
There were no signiﬁcant differences in the number of side-
effects reported between 1999 and 2004, and there had been no
serious reactions such as anaphylaxis or liver toxicity. Tiredness
still dominated but apart from that the picture was diverse
including concentration difﬁculties, nausea, sleeping difﬁculties
tremor and weight-gain or loss. No gender differences could be
found and no correlation with the type of AED used. We found no
signiﬁcant differences in cognitive side-effects between various
substances used.
The reported mean QLI score for overall QOL was 21.87 (S.D.
3.78), with approximately equal scores for men and women (21.44
compared to 22.00). The QLI score ranged from 11.70 to 29.43.
Participants who had recovered from epilepsy had a better QOL
than those still suffering from the disease (p < 0.05). The group
who received the lowest scores for QOL had the highest seizure-
frequency (p < 0.05). There were no signiﬁcant gender differences
regarding QOL. Participants with di- or poly-therapy scored lower
than participants with monotherapy (p < 0.05). There was no
correlation between QOL and the presence of AED side-effects in
general. The group who described cognitive side-effects had a
lower QOL than those who did not (p < 0.05).
4. Discussion
There have been considerable changes in the use of anti-
epileptic drugs over the last decade. Although traditional AEDs,
such as carbamazepine (CBZ) and valproate (VPA) remain ﬁrst drug
of choice, new AEDs have increased the ability to customise
treatment for each patient. We studied the situation for a group ofs with control, partial control and poor control of seizures.
Total (n)
nal New
AEDb
Poly-therapyc No
AED
Traditional
AEDa
New
AEDb
Poly-therapyc
4 1 6 42 6 5
3 3 21 27 11 6
2 1 3 18 4 3
0 3 1 8 6 5
1 1 0 6 1 3
0 3 0 0 4 8
7 3 9 66 11 11
3 9 22 35 21 19
m, and topiramate.
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present situation with their situation 5 years earlier. The drop-out
was quite high, especially amongmen. More women thanmen had
recovered from epilepsy, indicating a higher drop-out among men
who no longer suffered from seizures. One reason for this could be
that youngsters who have recovered from epilepsy do not want to
be reminded of the disease and their interest in participating in a
study was probably lower than before. In the group studied 21 out
of 97 participants had recovered. Sillanpa¨a¨ and Schmidt [1] studied
childhood epilepsy and found that a higher proportion recovered
than we found in this study. The actual chance of recovering from
epilepsy in adolescence is probably higher than our results indicate
because of the drop-outs in our study.
As expected adolescents were prescribed new AEDs to a greater
extent in 2004 than 5 years earlier. This study shows that there are
differences between the genders; more young women than young
men are now being treated with new-generation AEDs, but their
effectiveness in controlling seizures is lower in women. Apart from
teratogenicity, menstrual cycle disorders and reduced fertility
have been associated with AEDs [18], making the choice of AED for
women patients more complex. New AEDs appear to be more
favourable than the older ones for treating fertile women [12]. This
was the subject of intense discussion in the early 2000s resulting in
many neurologists changing AED treatment primarily in women-
patients. LTG is an alternative to VPA as ﬁrst drug of choice in
generalized idiopathic seizures inwomen of childbearing potential
[12]. The increase in use of LTG among women in this study can be
due to the introduction of new guidelines and correspond so the
diminished use of VPA. LTG may be less teratogenic in humans
than other AEDs, although orofacial clefts have been reported [19].
The effects of polytherapy appear to carry greater risks and VPA
appears to be associated with the highest risk of all during
pregnancy, becoming more evident as doses exceed 1000 mg/day
[19]. Data from pregnancy registers not only conﬁrm that VPA is
teratogenic but also that it may be associated with neuro-
developmental delay and autistic spectrum disorders in children
exposed to the drug during pregnancy [20]. The physician must
weigh beneﬁts of seizure freedom for their female patients against
the potential long-term consequences for the infants of these
patients [21].
Differences in cognitive side-effects between LTG and VPA have
been found by other researchers in favour of LTG [22], but could not
be conﬁrmed in this study. The participants in this study were
asked to describe side-effects, not to grade them, so we cannot
draw conclusions about the severity of the cognitive side-effects
for each substance. LTG has also the potential to improve quality-
of-life compared to VPA [23]. The SANAD study indicated that LTG
was clinically better than CBZ for time to treatment failure for
partial seizures [24]. In this study seizure frequency was higher for
women than for men and these women used new AEDs, usually
LTG, a fact that does not support the notion that new generation
AEDs are more effective than the old ones.
The participants in this study reported no reduction in QOL
compared with the US general population. This corresponds to
ﬁndings in other studies of QOL of epilepsy in remission [25].
Among studies focusing on patients with intractable epilepsy the
picture is different, with a substantial impact on QOL. The group in
this study had uncomplicated epilepsy andmost participants were
fairly well controlled regarding seizure frequency. The fact that
only a few participants suffered from intractable seizures can
explain the high QOL in the present study. Frequency of seizures is
the most important factor inﬂuencing QOL in this study of
adolescents. This has previously been shown in adults [26]. Senol
et al. [27] found that other important factors inﬂuence QOL in
particular fatigue and depression. Participants with polytherapy
have a lower QOL than the ones who use monotherapy. Adverseeffects of AED are common and can have a considerable impact on
QOL [28]. Cognitive side-effects in this studywere the only adverse
effects associated with a lower QOL. Benavente-Aguilar wrote in
2004 that medication neurotoxicity was associated with a lower
quality-of-life, over and above the effect of the severity of the
illness [29]. For young people who study or want to start working
the cognitive impairments are of particular concern. Boylan et al.
[30] have expressed concern that AED-related depression could
reduce QOL if seizures are treated over-enthusiastically. There is
also report of an improvement in QOL if AED can be withdrawn
[31]. In agreement with other studies we saw an increasing
incidence of side-effects with increasing numbers of agents used.
We studied these young people during the period in of their
lives whenmajor changes occur. That means that the life-situation
of the participants was in no way constant during the time of the
study. They moved, met new partners, began new studies and new
jobs. We assumed that this age-group would be more interested in
trying new drugs than older patients, but younger people are more
difﬁcult to trace and may also have a higher drop-out rate. The
questionnaires used were time-consuming, which can have
inhibited participation. The group was also heterogeneous,
consisting of people with epilepsy of different classiﬁcation being
treated with different combinations of medications, which results
in difﬁculty in drawing conclusions about any special group.
Despite this the study provides information about the use of new
AEDs in the clinical setting. AEDs are given to a miscellaneous
group of patients, which is reﬂected in this study.When a newdrug
is released it is ﬁrst used in combination with other drugs and only
later as mono-therapy. The treatment of epilepsy patients is and
should continue to be individualised. These factors however, make
it more difﬁcult to study this group in a natural manner.
One bias when using questionnaires might be that the patients
who choose to participate could be more seriously ill and because
of that more interested than those who declined. The fact that 21%
of those answering the questionnaires considered themselves to be
healthy also indicates that patients who had recovered from
epilepsy had an interest in participating.
In this study we could not show that seizure frequency in this
group of patients had improved since the introduction of new
generation AEDs. It may be that this study is too small to
demonstrate any difference. It can also reﬂect the severity of
epilepsy; participants with more severe epilepsy can have been
given new generation AED more generously, as the incentive to
make changes of medication is greater. It may also depend on the
fact that physicians have not yet learnt to use these drugs in an
optimal way. On the other hand, the QOL was normal for the
participants of this study meaning that the increase in number of
choices of AED can actually have given physicians the opportunity
to adjust treatment to suit the individual patient in a better way
than before. Many factors inﬂuence the well-being of our patients
making the choice of AED for each patient complex. More studies
are needed to better understand how these factors interact.
5. Conclusions
This study indicates that more women than men are treated
with new generation AEDs, and the increase in use of new AEDs
does not lead to a reduction in seizure frequency in young adults. It
further indicates that effectiveness in controlling seizures is lower
in women in the age-group studied. Further studies are required to
better understand how epilepsy-related factors interact.
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